Wegeners Granulomatosis

What is granulomatosis with polyangiitis (Wegener’s) (GPA)?

Granulomatosis with polyangiitis (Wegener’s) (GPA) is a rare disease of uncertain cause. It is the result of inflammation within the tissues called granulomatous inflammation and blood vessel inflammation ("vasculitis"), which can damage organ systems. The areas most commonly affected by GPA include the sinuses, lungs, and kidneys, but any site can be affected.

What is vasculitis?

Vasculitis is a general term that refers to inflammation of the blood vessels. When inflamed, the blood vessel may become weakened and stretch forming an aneurysm, or become so thin that it ruptures resulting in bleeding into the tissue. Vasculitis can also cause blood vessel narrowing to the point of closing off the vessel entirely. This can cause organs to become damaged from loss of oxygen and nutrients that were being supplied by the blood.

What are the features of GPA?

GPA primarily affects the upper respiratory tract (sinuses, nose, trachea [upper air tube]), lungs, and kidneys. Any other organ in the body can be affected as well.

The symptoms of GPA and their severity vary among patients. General signs of the disease may include:

Most patients first notice symptoms in the respiratory tract. Symptoms may include:

Other possible features include:

What causes GPA?

The cause of GPA is unknown. GPA is not a form of cancer, it is not contagious, and it does not usually occur within families. Evidence from research laboratories strongly supports the idea that the immune system plays a critical role in GPA such that the immune system causes blood vessel and tissue inflammation and damage.

Who is affected by GPA?

GPA can occur in people of all ages. The peak age groups affected are from 40-60 years. It appears to affect men and women equally.

How is GPA diagnosed?

GPA has symptoms similar to a number of other disorders, which may make it difficult to diagnose. However, for the most effective and successful treatment, early diagnosis is critical.

Once the diagnosis of GPA is suspected, a biopsy (tissue sample) of an affected area is often performed to try to confirm the presence of vasculitis. Biopsies are only recommended for organ sites in which there are abnormal findings present by examination, laboratory tests, or imaging.

It is the combination of symptoms, results of physical examinations, laboratory tests, X-rays, and sometimes a biopsy (sample) of affected tissue (skin, nasal membranes, sinus, lung, kidney or other sites) that together prove the diagnosis of GPA. Following treatment, these factors are also critical in judging whether the disease is active or in remission.

A positive blood test for antineutrophil cytoplasmic antibodies (ANCA) can support a suspected diagnosis of the disease. However, this blood test does not by itself prove the diagnosis of GPA or determine disease activity.

Sometimes the lungs may be abnormal even though there are no symptoms such as cough or shortness of breath. If symptoms of GPA are apparent, but not from the lungs, one quarter to one third of patients may still have unexpected lung abnormalities detected on imaging tests (conventional X-rays or a CT scan). Therefore, it is important to have lung images performed if active GPA is suspected -- even if you don't have any symptoms of lung disease.

How is the disease treated?

Because GPA is often a life-threatening disease, it is treated with a variety of powerful drugs that have been shown to be life-saving. Medications that suppress the immune system form the foundation of treatment for GPA. There are a variety of immunosuppressive medications that are used in GPA, each of which has individual side effects.

People with GPA who have critical organ system involvement are generally treated with corticosteroids combined with another immunosuppressive medication such as cyclophosphamide (Cytoxan ®) or rituximab (Rituxan®). In patients who have less severe GPA, corticosteroids and methotrexate can be used initially. The goal of treatment is to stop all injury that is occurring as a result of GPA. If disease activity can be completely "turned off," this is called "remission." Once it is apparent that the disease is improving, doctors slowly reduce the corticosteroid dose and eventually hope to discontinue it completely. When cyclophosphamide is used, it is only given until the time of remission (usually around 3 to 6 months), after which time it is switched to another immunosuppressive agent, such as methotrexate, azathioprine (Imuran®), or mycophenolate mofetil (Cellcept®) to maintain remission. The treatment duration of the maintenance immunosuppressive medication may vary between individuals. In most instances, it is given for a minimum of 1 to 2 years before consideration is given to possibly slowly reduce the dose toward discontinuation.

All of these medications are also used to treat other medical conditions. Azathioprine and mycophenolate mofetil are used to prevent organ transplant rejection. Methotrexate is used to treat rheumatoid arthritis and psoriasis. Both cyclophosphamide and methotrexate are given at high doses as a treatment for certain types of cancer and therefore are sometimes referred to as "chemotherapy." In cancer treatment, these medications work by killing or slowing the growth of rapidly multiplying cancer cells. In vasculitis, these medications are given at doses that are 10 to 100 times lower than those used to treat cancer, and their primary effect is to influence the behavior of the immune system in a manner that results in immunosuppression. Rituximab belongs to a class of medications called biologic agents that target a specific element of the immune system. Recent studies found that rituximab was as effective as cyclophosphamide for treating severe active GPA.

What are some side effects associated with treatment?

Because these medications suppress the immune system, there is an increased risk of developing serious infections. Each immunosuppressive drug also has a unique set of potential side effects. Monitoring for the side effects associated with each drug is critical to prevent or minimize their occurrence. Also, the fact that a patient may initially tolerate treatment does not guarantee that tolerance will remain the same over time. This makes ongoing monitoring essential, and in some instances, monitoring for long-term side effects may be important even after the drug is stopped.

What is the outlook for people with GPA?

After achieving remission, it is possible for GPA to recur (often referred to as a "relapse"). Relapses occur in about 50-70% of people with GPA. Such relapses may be similar to what the patient experienced at the time of their diagnosis or they may be different. The likelihood of experiencing a severe relapse can be minimized by prompt reporting to the doctor of any new symptoms, regular doctor follow-up, and ongoing monitoring with laboratory tests and imaging. The treatment approach for relapses is similar to that of newly diagnosed disease.

GPA is a very serious disease, and its treatment carries significant risks. However, treatment is life-saving for almost everyone when the diagnosis is made in a timely fashion and appropriate treatment instituted. This includes regular monitoring of disease activity and possible medication toxicity.

Prior to recognizing effective therapy in the 1970s, half of all patients with this illness died within 5 months of diagnosis. Today, more than 80% of treated patients are alive at least eight years later. For many people with GPA, long term survival has been seen with many also being able to lead relatively normal lives. If past is prelude to the future, ongoing research will lead to further discoveries and even better treatment.



This information is provided by the Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition. For additional health information, please contact the Center for Consumer Health Information at the Cleveland Clinic (216) 444-3771 or toll-free (800) 223-2273 extension 43771. If you prefer, you may visit www.clevelandclinic.org/health/ or www.clevelandclinicflorida.org. This document was last reviewed on: